9. Evidence of current cardiovascular, central nervous system, hepatobiliary disease including history of biliary tree disorders and/or cholecystectomy, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma, hypoxemia, hypertension, seizures, or allergic skin rash. There is any finding in the participant's medical history, physical examination, or safety laboratory test results (including elevated alkaline phosphatase [ALP], elevated bilirubin, elevated gamma-glutamyl transferase [GGT], elevated 5'-nucleotidase, elevated sorbitol dehydrogenase, or abnormal urine osmolality) that in the judgment of the principal investigator represents a reasonable suspicion of a disease that would contraindicate taking TAK-041, or that might interfere with the conduct of the study. This includes, but is not limited to, peptic ulcer disease, seizure disorders, and cardiac arrhythmias